572 related articles for article (PubMed ID: 29028766)
1. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
[TBL] [Abstract][Full Text] [Related]
2. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zacharis A; Grüllich C
Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
[TBL] [Abstract][Full Text] [Related]
4. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for immunotherapy in urological cancers.
Gust KM; Resch I; D'Andrea D
Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
[TBL] [Abstract][Full Text] [Related]
7. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
[TBL] [Abstract][Full Text] [Related]
8. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
9. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Sonpavde G; Manitz J; Gao C; Tayama D; Kaiser C; Hennessy D; Makari D; Gupta A; Abdullah SE; Niegisch G; Rosenberg JE; Bajorin DF; Grivas P; Apolo AB; Dreicer R; Hahn NM; Galsky MD; Necchi A; Srinivas S; Powles T; Choueiri TK; Pond GR
J Urol; 2020 Dec; 204(6):1173-1179. PubMed ID: 32552295
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials.
Hsu MM; Balar AV
Clin Genitourin Cancer; 2019 Jun; 17(3):e618-e626. PubMed ID: 31005473
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma.
Powles T; Walker J; Andrew Williams J; Bellmunt J
Cancer Treat Rev; 2020 Jan; 82():101925. PubMed ID: 31785413
[TBL] [Abstract][Full Text] [Related]
12. Recent developments in the treatment of advanced bladder cancer.
Godwin JL; Hoffman-Censits J; Plimack E
Urol Oncol; 2018 Mar; 36(3):109-114. PubMed ID: 29395952
[TBL] [Abstract][Full Text] [Related]
13. Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: where we stand and where we go.
Gevaert T; Cimadamore A; Eckstein M; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
Future Oncol; 2019 Jul; 15(19):2199-2202. PubMed ID: 31213082
[No Abstract] [Full Text] [Related]
14. Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma.
Park KJ; Lee JL; Yoon SK; Heo C; Park BW; Kim JK
Eur Radiol; 2020 Oct; 30(10):5392-5403. PubMed ID: 32394281
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers.
Gill DM; Agarwal N
Urol Oncol; 2017 Dec; 35(12):676-677. PubMed ID: 29054496
[TBL] [Abstract][Full Text] [Related]
16. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
17. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Zschäbitz S; Niegisch G
Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
[TBL] [Abstract][Full Text] [Related]
18. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Teo MY; Seier K; Ostrovnaya I; Regazzi AM; Kania BE; Moran MM; Cipolla CK; Bluth MJ; Chaim J; Al-Ahmadie H; Snyder A; Carlo MI; Solit DB; Berger MF; Funt S; Wolchok JD; Iyer G; Bajorin DF; Callahan MK; Rosenberg JE
J Clin Oncol; 2018 Jun; 36(17):1685-1694. PubMed ID: 29489427
[TBL] [Abstract][Full Text] [Related]
19. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
[TBL] [Abstract][Full Text] [Related]
20. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
Todenhöfer T; Boegemann M
Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]